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ABSTRACT
Thyroid hormone exerts profound effects on the insulin-like growth
factors (IGFs)/IGF factor I receptor (IGF-IR) system through its ac-
tion on the production of IGF-I peptide and IGF-binding proteins.
Most of these actions are mediated by the direct control of pituitary
GH gene by thyroid hormone. In this work, we have analyzed the
possible effect of hypothyroidism on the expression of IGF-IR gene,
both in adult and developing animals. Our results show that in the
lung and heart, thyroid hormone exerts a negative effect on IGF-IR
gene expression in the adult animals and during perinatal life (from
day 15 onwards). This negative effect is exerted at different levels. In
the heart, this regulation occurs at a pretranslational level, indicated
by the fact that parallel changes in the number of membrane IGF-I
receptors and IGF-IR transcripts were observed, whereas in lung, no
effect of thyroid hormone was noted in the amount of IGF-IR tran-
scripts, suggesting a translational or posttranslational control. GH
does not seem to mediate T3 effects on this gene. In contrast, retinoic
acid increases the expression of IGF-IR gene at a transcriptional or
posttranscriptional level in adult lung and heart. Because the IGFs/
IGF-IR system is depressed in hypothyroid animals, the specific in-
crease in the number of IGF-IRs in the lung andheart of these animals
could represent a mechanism to ameliorate the negative effects of
hypothyroidism on these important organs. (Endocrinology 138:
1194–1203, 1997)
T3PLAYS an important role in growth and developmentof most vertebrate tissues (1). The majority of the ac-
tions of T3 aremediated by nuclear receptors present in those
tissues. These receptors are members of the nuclear receptor
superfamily, which includes the receptors for steroid hor-
mones, vitamin D3, retinoids, and the so-called orphan re-
ceptors, without known ligand (2). Several isoforms of thy-
roid hormone receptors are produced from two different
genes (3). These proteins are ligand-dependent transcription
factors that control directly the expression of a limited num-
ber of genes, those containing a thyroid response element
(TRE) (4, 5) in their promoter. Thyroid hormone receptors
also can exert direct actions on gene expression through
protein-protein interaction with other transcription factors
(6). T3 control of these specific genes most probably initiates
a cascade of events in which many other genes are indirectly
influenced by thyroid hormone. A clear example of this in-
direct control is the transcriptional regulation by T3 of pitu-
itary GH gene and the subsequent effects of this hormone.
Therefore, the knowledge of which genes are directly or
indirectly regulated by T3 in the different tissues is necessary
for a complete understanding of thyroid hormone action.
Insulin-like growth factor I (IGF-I) is involved in tissue
growth and development during fetal and neonatal life and
acts as a mitogen and a differentiation factor (7), mediating
many of the effects of pituitary GH (8). The plasma mem-
brane receptor for IGF-I (IGF-IR) is coded by a single gene
and shows considerable sequence homology and functional
similarity with the insulin receptor. Both receptors have het-
erotetrameric structures formed by two a and two b subunits
with a tyrosine kinase domain in the cytoplasmic portion of
the molecules (9). IGF-IR also binds IGF-II, although with
lower affinity (10), and it is thought to mediate many of the
effects of this growth factor (11). IGF-binding proteins
(IGFBPs) bind circulating IGF-I and IGF-II with high affinity
modulating their receptor-binding properties and their bio-
logical actions (12). IGFBPs are coded by at least six different
genes that are expressed in a tissue- and developmental-
specific manner (13). All these molecules (IGF-I, IGF-II, IGF-
IR, and IGFBPs) constitute the IGFs/IGF-IR system, which
acts in an endocrine and auto/paracrine manner and plays
a major role in vertebrates’ growth. This system is a target of
thyroid hormone action, because it is known that T3 regulates
the expression of IGF-I and several IGFBP genes in diverse
tissues (14, 15), and it is thought to mediate many of the
thyroid hormone effects on somatic growth (14). The effects
of thyroid hormone on the IGFs/IGF-IR system are mainly
exerted through its control of GH gene expression (16), al-
though GH-independent mechanisms also have been de-
scribed (17).
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In this work, we have studied whether in addition to IGF-I
and IGFBP genes, the IGF-IR gene could be under thyroid
hormone control throughout development and in adult life.
We have focused our study on the lung and heart, two tissues
that are important targets of both thyroid hormone (18, 19)
and the IGFs/IGF-IR system (20, 21).
Our results showed that in the rat, IGF-IR gene expression
is repressed by thyroid hormone in the two tissues studied,
lung and heart, from day 15 of postnatal life. Consequently,
IGF-I binding was increased in hypothyroid animals and
diminished after T3 administration to these animals. The
changes in IGF-IR messenger RNA (mRNA) levels in the
heart paralleled those of IGF-I binding. However, this was
not the case in the lung, where T3 had no effect on the content
of IGF-IR transcripts, suggesting that this hormone acts at
different levels in both tissues. On the other hand, retinoic
acid (RA) increased the expression of IGF-IR gene at a pre-
translational level in both tissues in adult animals. Finally,
GH does not seem to mediate T3 effects on this gene.
Materials and Methods
Animals
Female Wistar rats were mated and the day of appearance of the
vaginal plugwas considered as day zero of fetal age. To induce fetal and
neonatal hypothyroidism, dams were given 0.02% methyl mercapto-
imidazole (MMI) in their drinking water at day 9 of pregnancy. MMI
administration was continued throughout gestation and the lactating
period. At postnatal day 5, pups were injected with 131I (150 mCi/100 g
of BW) to destroy all thyroidal tissue. Adult hypothyroidism was in-
duced withMMI treatment for 3 weeks. With these treatments, cytosolic
T3 fell below detectable levels. Treatment with T3 or RA was performed
by ip injection of 200 mg T3 or 100 mg RA/100 g of BW. Control rats
received an injection of the vehicle. The rats were decapitated at the
indicated ages and the tissues rapidly removed and frozen at280Cuntil
use, except formembrane preparation, forwhich fresh tissueswere used.
Membrane isolation
Lung and heart membranes were prepared, as previously described
(22, 23). Briefly, the lungs were homogenated with a polytron in 10 vol
buffer L (10mmHEPES pH 7.5, 30mmNaCl, 1 mmDTT, and 5mm PMSF
as protease inhibitor), the homogenates were filtered through a double
gauze, then layered over a 41% (wt/vol) sucrose solution in buffer L, and
centrifuged at 95,000 3 g for 1 h. The membrane fraction was recovered
from the interface, washed twice with L buffer, resuspended in 10 mm
HEPES pH 7.4, and kept at 280 C until use. Hearts were homogenized
with a polytron in 3.5 vol buffer H (10 mm Imidazole/HCl pH 7.0, 0.6
m sucrose, and 5 mm PMSF as protease inhibitor), centrifuged 30 min at
12,000 3 g, and the supernatants were diluted 2.5-fold with MOPS/KCl
buffer (20 mmMOPS pH 7.4 and 160 mm KCl) and centrifuged again 1 h
at 96,000 3 g. Pellets were resuspended in MOPS/KCl buffer (4 ml/g),
layered on a 30% (wt/vol) sucrose solution containing 0.1mTris-HCl pH
8.3, 50 mm Na-pyrophosphate and 0.3 m KCl, and centrifuged 1.5 h at
95,000 3 g. The membrane fraction was recovered from the interface,
washed with MOPS/KCl buffer, resuspended in the same buffer, and
kept at 280 C until use. All the steps described for membrane prepa-
ration were carried out at 4 C. Protein content was determined by the
method of Bradford (24). The activity of the enzyme 59-nucleotidase (EC
3.1.3.5.) (25) was used as an index of membrane purification.
Binding assay
Membrane fractions (100 mg protein) were incubated with 1.1–1.5 3
10210 m [125I]-IGF-I (2000 Ci/mmol; Amersham Corp., Aylesbury, UK)
at 0–2 C during 16–20 h in Krebs HEPES solution (NaCl 118 mm, KCl
5 mm, KH2PO4 1.2 mm, MgSO4 1.2 mm, CaCl2 2.5 mm, and HEPES 25
mm, pH 7.4), containing 1% BSA and 0.5 mg/ml bacitracin. Bound and
free polypeptides were separated by centrifugation, and the membrane
protein recovered was determined to correct binding values. The re-
covery was approximately 60% of the initial amount of protein and no
differences were found among the different samples. Nonspecific bind-
ing was considered as the radioactivity bound in the presence of 1027
m unlabeled IGF-I. For saturation analysis, membranes were incubated,
as described, with [125I]-IGF-I (1.1–1.6 3 10210 m) and increasing con-
centrations of unlabeled IGF-I (10210 m-5 3 1027 m). The data were
analyzed with the computer program Ligand and the affinity and num-
ber of binding sites calculated. Degradation of [125I]-IGF-I, as measured
by 10% trichloroacetic acid precipitation, was negligible (2.5%).
Affinity labeling and SDS-PAGE
For IGF-I receptor labeling, membrane-bound [125I]-IGF-I was chem-
ically cross-linked to the receptor with the homobifunctional reagent,
disuccinimidyl suberate (Pierce Chemical, Rockford, IL), at a final con-
centration of 0.5 mm. Affinity-labeled membranes were solubilized and
analyzed by SDS-PAGE in 7.5% acrylamide gels under reducing con-
ditions (2.5% b-mercaptoethanol) (26). The gels were dried, exposed to
x-ray films, and the signal in the film quantified by computer-assisted
densitometry.
FIG. 1. Effect of hypothyroidism on
IGF-I binding to lung and heart mem-
branes during development. Lung and
heart membranes from control (C) and
hypothyroid animals (Tx) were pre-
pared, as indicated in Materials and
Methods. F, Fetuses; N, neonates; A,
adults. [125I]-IGF-I binding (1.13 10210
M) was determined, and the values
given in the text are the average of spe-
cific binding of at least three different
samples, or two for 20-day-old fetuses.
The bars represent SD. *, P , 0.05; **,
P , 0.01 vs. C.
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Ribonuclease (RNase) protection assay
Total RNA from the different tissues was obtained according to the
method of Chomczynski and Sacchi (27) and checked for integrity by
1% agarose gel electrophoresis. For RNase protection assay, a rat
homologous IGF-I receptor complementary DNA (cDNA) probe of
510 bp was generated by PCR amplification of rat brain cDNA.
(Forward primer: 59-AAA AGG AAT GAA GTC TGG CTC C-39,
reverse primer: 59-GTA GTT ATT GGA CAC CGC ATC C-39). The
amplified fragment was subcloned in the pCR vector (Invitrogen
Corporation, San Diego, CA) and sequenced in an Applied Biosys-
tems 373A DNA Sequencer, using the dideoxynucleotide chain-ter-
minator method. A [32P]-labeled cRNA probe of 643 nucleotides was
generated by SP6 RNA polymerase and [a-32P]UTP (400 Ci/mmol;
Amersham Corp., Aylesbury, UK), and 5 3 105 cpm were allowed to
hybridize overnight at 45 C with 20 mg of total RNA. A 248-bp
cyclophilin cRNA (from 1–248) (28), labeled with [a-32P]UTP (400
Ci/mmol), was used as control. The RNA was then digested and the
remaining fragments separated in a sequencing gel, as described by
Sambrook et al. (29). The gels were exposed and the autoradiograms
quantified by computer-assisted densitometry. For quantitation cor-
rections, the values of cyclophilin signal were used. We have ob-
served previously that cyclophilin values are not modified in lung
and heart as a consequence of hypothyroidism or T3 treatment (data
not shown). Development caused a small decrease in the ratio cy-
clophilin/28S rRNA signal; this was taken into account for the final
quantitation analysis (see Figs. 5 and 6), where mRNA IGF-IR signal
was compared at different ages.
Results
Effect of thyroid hormone on IGF-I binding
Membranes from lung and heart of control and hypothy-
roid animals were isolated at the following ages: 20-day-old
fetuses (F-20) and 5- (N-5), 15- (N-15), and 30-day-old (N-30)
neonates and adult (A) animals. The binding of IGF-I was
determined, as indicated in Materials and Methods, and the
results are shown in Fig. 1. In lung, IGF-I binding increases
after birth (30 fmol/mg protein in F-20 and 41 fmol/mg
protein in N-5) and decreases in the adult animal (17
fmol/mg protein). Congenital hypothyroidism did not cause
any significant change to lung membrane IGF-I binding in
fetuses and N-5 and N-15 animals. However, a marked in-
crease in binding was observed in the membranes of hypo-
thyroidN-30 and adult animals comparedwith age-matched
controls (1.8- and 1.6-fold increases, respectively). The IGF-I
binding profile in heart membranes differed from that ob-
served in the lung. The highest binding activitywas observed
in N-15 (47.5 fmol/mg protein), and a more pronounced
reduction than that in the lung was observed in N-30 (25.8
fmol/mg protein) and adult (12.79 fmol/mg protein) heart
membranes. Hypothyroidism, as seen in lung, caused a sig-
nificant increase of IGF-I binding inN-30 and adults (1.4-fold
FIG. 2. Effect of T3 administration on
IGF-I binding to lung (A) and heart (B)
membranes. Lung and heart mem-
branes from control (C), hypothyroid
(Tx), and hypothyroid animals injected
daily with T3 (200 mg/100 g BW)
(Tx1T3) were obtained, as indicated in
Materials and Methods. Animals were
killed at the indicated times after the
first injection. N, Neonates; A, adults.
[125I]-IGF-I binding (1.13 10210 M) was
determined, and the values given are
the average of specific binding of at
least three different samples. The bars
represent SD. *, P , 0.05; **, P , 0.01;
***, P , 0.001 vs. Tx.
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increase in both cases compared with age-matched controls)
but not in the other groups studied (Fig. 1).
In the hypothyroid animals, the changes observed in IGF-I
binding to lung and heart membranes were not caused by
differences in IGF-I degradation or an artifact of membrane
purification. The rate of degradation was the same in control
and hypothyroid membranes (2.5%), and 59-nucleotidase ac-
tivity was similarly enriched in both groups (9- and 11-fold
in lung and heart, respectively), indicating no differences in
the membrane fraction selected.
To determine whether the observed effect of hypothyroid-
ism on IGF-I binding to lung and heart membranes could be
corrected by thyroid hormone treatment, hypothyroid N-30
and adult rats were injected daily with a saturating dose of
T3, killed at the indicated times, and IGF-I binding deter-
mined. The results for lungmembranes are shown in Fig. 2A.
Twenty-four hours after T3 injection, a significant reduction
in IGF-I binding was observed in N-30 (from 67.5 to 46.7
fmol/mg protein), and after 48 h, the binding was indistin-
guishable from control animals. In the adults, T3 reduced
IGF-I binding only after 72 h of T3 administration, and no
significant effect was observed within 24 h, suggesting a
delayed response to T3 in these animalswhen comparedwith
the neonates. Also, N-5 and N-15 hypothyroid rats were
injected with T3 and, as shown in Fig. 2A, a decrease in
binding was detected in N-15 after 48 h of T3 administration,
suggesting that, at this age, the animals are sensitive to T3
action, although no differences could be observed on steady-
state values. On the contrary, N-5 hypothyroid neonates did
not respond to T3 treatment (data not shown). In heart mem-
branes, as shown in Fig. 2B, T3 administration to hypothyroid
N-30 and adult rats decreased IGF-I binding to reach control
values within 24 h. In hypothyroid N-15, T3 also reduced
IGF-I binding far below control levels after 24 h (18.4
fmol/mg protein compared with 47.48 fmol/mg protein in
controls), although, as observed in the lung, no differences
were seen in steady-state values.
It is known that IGF-I also binds to IGF-II and insulin
receptors, althoughwith lower affinity. To eliminate the pos-
sibility of IGF-I cross-binding with these receptors, cross-
linking experiments were performed using lung and heart
membranes. As shown in Fig 3, a labeled band of approxi-
mately 130 kDa was observed in lung membranes of N-30
and adults in all the experimental groups studied. This band
was displaced by the simultaneous incubation with unla-
beled IGF-I (1027 m), but only slightly by insulin (1026 m),
indicating that it corresponds to the a subunit of the IGF-I
receptor. Similar results were observed using heart mem-
branes (data not shown). A labeled band of approximately
260 kDa was observed in all samples analyzed and probably
represents IGF-I receptor a subunit dimmers, because its
levels are proportional to the 130 kDa-band.
Scatchard analysis of IGF-I binding was performed to de-
termine whether the increased binding observed in hypo-
thyroid animals was caused by a change in the number of
binding sites and/or changes in affinity. As shown in Fig. 4,
curvilinear plots, probably reflecting a negative cooperativ-
ity in IGF-I binding (30), were obtained for all the groups
studied. The number of total IGF-I binding sites in hypo-
thyroid lung membranes compared with the control were
2.7-fold higher in N-30 and 2.4-fold higher in adults (Bmax
470 and 160 fmol/mg protein in control N-30 and adults,
respectively) (Fig. 4A). The administration of T3 to hypothy-
roid animals decreased the number of IGF-I receptors. In the
heart, a 3.2-fold increase was observed in N-30 hypothyroid
animals (Bmax 620 fmol/mg protein in controls) (Fig. 4B).
The high affinity-binding constant was similar in all the
groups studied (kDa 1.06 nm). These results clearly indicate
that the increases in IGF-I binding (10210m) in lung and heart
membranes of hypothyroid animals were caused by an in-
crease in the number of binding sites.
Effect of thyroid hormone on IGF-I receptor mRNA content
To analyze the mechanism by which thyroid hormone
affected IGF-I binding, we determined the amount of IGF-IR
transcripts in total RNA isolated from lung and heart of
control and hypothyroid animals at the indicated ages. The
amount of IGF-I mRNA was determined by RNase protec-
tion assay, as indicated in Materials and Methods, and in the
same assay, the amount of cyclophilin was determined and
used as a control. The results are shown in Figs. 5 and 6. The
developmental profiles of heart and lung IGF-IR mRNA lev-
els were similar to those observed for IGF-I binding. A mod-
erate increase of IGF-IR mRNA after birth and a decrease in
the adults suggests a developmental control of this gene at
a pretranslational level.
Hypothyroidism did not significantly alter the levels of
IGF-IR mRNA in lung during the period studied, although
the average tends to be higher in the hypothyroid group in
N-30, in accordancewith IGF-I binding data, and lower in the
FIG. 3. [125I]-IGF-I cross-linking to lung membranes. Bound [125I]-
IGF-I (1.5 3 10210 M) in the absence or presence of unlabeled IGF-I
(1027 M) or insulin (1026 M) was chemically cross-linked to its receptor
with 0.5 mM disuccinimidyl suberate. The samples (50 mg protein/
lane) were solubilized under reducing conditions and subjected to
SDS-PAGE in 7.5% acrylamide slab gels. N-30, 30 days-old neonates;
A, adults; C, control; Tx, hypothyroid.
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adults, in spite of the higher binding activity (Fig. 5B). In
contrast to the observations in lung and in agreement with
the binding values, a significant increase in IGF-IR mRNA
content in the heart was observed in hypothyroid N-30 and
adult rats (2.8- and 1.8-fold increase, respectively) (Fig. 6B).
When the amount of IGF-IR mRNA was determined in
T3-injected hypothyroid N-15, N-30, and adult animals, no
changes were observed in the lung (Fig. 7A), even after 72 h
of treatment, a period during which a decrease in IGF-I
bindingwas observed in all groups. These results confirm the
lack of effect of T3 on the content of IGF-IR transcripts in lung
and suggest that IGF-IR gene is controlled by thyroid hor-
mone at the translational and/or posttranslational level in
this tissue. In keeping with thyroid hormone repression of
IGF-IR binding, T3 injection also decreased IGF-IR mRNA
content in the heart of hypothyroid animals at all ages stud-
ied (Fig. 7B). In N-15 animals, a marked 2.6-fold decrease in
the content of IGF-IR transcripts was already observed 12 h
after T3 injection. These results indicate that in heart, in
contrast with lung, thyroid hormone exerts its effects on
IGF-IR gene at a pretranslational level, and changes in IGF-IR
mRNA are a probable cause for the observed decrease in
binding sites.
Effect of GH on IGF-I binding and IGF-I receptor mRNA
content
It is well established that GH production is under T3 con-
trol in rat pituitary of both adult and developing rats (16),
and it has been shown that GH alters IGF-I binding in some
systems (31, 32). Given these evidences, we investigated
whether the effect of thyroid hormone on IGF-IR could be
mediated by GH.We studied the effect of GH administration
on IGF-I binding and IGF-IR mRNA content in lung and
heart. For this purpose, N-30 hypothyroid rats were sc in-
jected once daily with human GH (50 mg/100 g of BW), and
FIG. 4. Scatchard analysis of IGF-I binding to lung (A) and heart (B) membranes. IGF-I binding was analyzed at different polypeptide
concentrations (10210 M-5 3 1027 M) and the values represented according to Scatchard. N-30, 30 day-old neonates; A, adults; M, control; E,
hypothyroid; f, hypothyroid injected with T3 and killed 48 h (N-30) and 72 h (A) later.
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different groups of animals were killed 24 and 72 h later to
determine IGF-I binding and IGF-IR mRNA content. As
shown in Fig. 8A, GH had no effect on IGF-I binding in either
tissue. No alterations in IGF-I degradation or in 59nucleoti-
dase activity during membrane purification was observed in
GH-treated animals. Moreover, no alterations in IGF-IR
mRNA content were observed in the heart and only a mod-
erate increase in the lung was detected after 72 h (Fig. 8B),
in spite of the fact that no changes were observed on IGF-I
binding to lung membranes. All these results suggest that
GH does not mediate the observed alterations on IGF-IR
expression caused by thyroid hormone.
Effect of RA on IGF-I binding and IGF-IR mRNA content
in lung and heart
RA receptor is a close relative of thyroid hormone receptor;
they bind to similar hormone regulatory elements, can het-
erodimerize, and frequently can regulate the same set of
FIG. 5. Effect of hypothyroidism on IGF-IR mRNA levels in lung
during development; Representative RNase protection experiment
(A) and densitometric quantification of IGF-IR mRNA content (B).
Total RNA was isolated from lung of control (C) and hypothyroid (Tx)
animals at the indicated ages and IGF-IRmRNA content determined,
as described in Materials and Methods. F, Fetuses; N, neonates; A,
adults; M, DNA ladder; Y, yeast tRNA (10 mg) was used for hybrid-
ization. Values refer to the intensity of the band in the adult control
and represent the average of three (F-20), four (N-5 and N-15), and
eight (N-30 and A) different samples. The bars represent SD.
FIG. 6. Effect of hypothyroidism on IGF-IR mRNA content in heart
during development; representative RNase protection experiment (A)
and densitometric quantification of IGF-IR mRNA levels (B). Total
RNA was isolated from heart of control (C) and hypothyroid (Tx)
animals at the indicated ages and IGF-IRmRNA content determined,
as described in Materials and Methods. F, Fetuses; N, neonates; A,
adults. M, DNA ladder. Y, yeast tRNA (10 mg) was used for hybrid-
ization. Values refer to the intensity of the band in the adult control
and represent the average of 3 (F-20) and 4 (neonates and adult)
different samples. The bars represent SD. *, P , 0.05; **, P , 0.01
vs. C.
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genes in a similar way (33). For this reason, RA (100 mg/100
g BW was injected ip into hypothyroid adult rats and then
IGF-I binding and the amount of IGF-IR mRNA determined.
As shown in Fig. 9A, RA increased IGF-IRmRNA levels after
24 h of treatment, both in heart and lung of hypothyroid
animals, with a higher effect in the heart (3.7-fold compared
with 2.4-fold in lung). In agreement with the increase in
IGF-IRmRNAcontent, IGF-I bindingwas augmented in lung
membranes after RA treatment (Fig. 9B). Scatchard analysis
indicated that this increase in IGF-I binding was the conse-
quence of a higher number of IGF-IR (data not shown). These
results suggest that RA regulates IGF-IR gene at a pretrans-
lational level in both tissues.
Discussion
In this work, we have demonstrated that the expression of
IGF-I receptor is under thyroid hormone control in the lung
and heart of neonatal and adult rats. These results, in addi-
tion to other known effects of thyroid hormone on the ex-
pression of IGF-I and IGFBPs genes in humans and exper-
imental animals, imply a tremendous dependence of the
IGFs/IGF-IR system on the thyroidal state.
The parallelism between the developmental profile of
IGF-I binding and IGF-IR mRNA content in lung and heart
suggests a control of the IGF-IR gene at a pretranslational
level, as previously indicated (34). Our results are in agree-
ment with reported data of IGF-I binding in developing rat
lung (35) and heart membranes (36), although changes in
affinity also have been described (36). An effect of thyroid
hormone on IGF-I binding, in lung and heart during devel-
opment, was not observed until day 15 of postnatal life,
although in this group of animals, the administration of a
saturating dose of T3 was required to detect a decrease in
binding, in contrast to the N-30 animals, where an increase
in IGF-I binding was observed in hypothyroid animals com-
pared with controls. This suggests that IGF-I receptor gene
responsiveness to thyroid hormone is established between
days 5 and 15 of postnatal life, and it is maintained through-
out adult life. The negative effect exerted by thyroid hormone
on IGF-IR gene expression in lung and heart is in contrast to
the reported effects of T3 on IGF-I binding in other systems.
In adult rats, it has been shown that T3 increases IGF-I bind-
ing in the pituitary (37), and also, T3 increases IGF-I binding
in smooth muscle (38) and pituitary tumor cells in culture
(39). This differential response indicates that the effect of
thyroid hormone is tissue specific, which may be very im-
portant in relation to IGF-I regulation of specific functions.
Another result that supports this conclusion is that we have
not observed any effect of thyroidal state on IGF-I binding
and IGF-IR mRNA in the cerebral cortex of developing rats
and in the skeletal muscle of adult animals (data not shown).
Interestingly, T3 acts by different mechanisms in lung and
FIG. 7. Effect of T3 administration on
IGF-IR mRNA content in lung (A) and
heart (B). Total RNA was isolated from
lung and heart of control (C), hypothy-
roid (Tx) and hypothyroid animals in-
jected daily with T3 (200 mg/100 g BW)
(Tx1T3), and killed at the indicated
times. IGF-IR mRNA content was de-
termined, as indicated inMaterials and
Methods. N, Neonates; A, adults.
IGF-IR mRNA content was quantified
by computer-assisted densitometry.
Values refer to the intensity of the band
in the adult control and represent the
average of at least four different sam-
ples. The bars represent SD. *, P ,
0.05;* **, P , 0.01 vs. Tx.
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heart. In heart, IGF-IR mRNA and IGF-I binding change in
parallel, both in steady-state and after hormone administra-
tion, suggesting a control of this gene at a pretranslational
level. In contrast, in the lung, no significant differences were
observed in IGF-IRmRNA content, in spite of the differences
observed in IGF-I binding, suggesting an effect of thyroid
hormone on translational efficiency or half-life of the protein.
In the literature, both levels of control have been reported for
IGF-IR gene. Proportional changes inmRNA levels and bind-
ing have been shown in diverse rat tissues during fasting (40)
and in cells in culture after the administration of progestins
(41). Regulation at a translational or posttranlational level
has been shown also in mesangial cells from normal and
diabetic mice (42). The structure of IGF-I receptor mRNA
could provide the molecular basis for the control of this gene
at the translational level. Rat IGF-IR mRNA has a long 59-
untranslated region, a G/C rich sequence with an open read-
ing frame of 84 nucleotides (43), that has been implicated in
the regulation of translation (44). Unusually long 59-untrans-
lated regions have been observed in other genes regulated at
the level of translation (45). In fact, thyroid hormone also has
been shown to control gene expression at a translational
and/or posttranslational level (46). Although the mecha-
nisms for T3 control at these two levels are not well estab-
lished, the mechanism is probably indirect and implies the
existence of previous control by T3 of other genes at a tran-
scriptional level.
Although it has been shown previously that IGF-IR could
FIG. 8. Effect of GH administration on IGF-I binding (A) and IGF-IR
mRNA content (B) in lung and heart of N-30 hypothyroid rats. Hy-
pothyroid 30 day-old neonatal rats were injected daily sc with human
GH (50 mg/100 g BW) and groups of animals were killed 24 and 72 h
later. Membranes and total RNA were isolated from lung and heart
and IGF-I binding and IGF-IR mRNA content determined, as indi-
cated in Materials and Methods. C, Control; Tx, hypothyroid. Given
values represent the average of four (C and Tx) or three (GH injected
animals) different animals in (A) and four in (B). The bars represent
SD. **, P , 0.01 vs. Tx.
FIG. 9. Effect of RA administration to hypothyroid adult rats on
IGF-IR mRNA content (A) and IGF-I binding (B). A, A representative
RNase protection assay; B, binding values for at least three different
lung membrane samples. Adult hypothyroid animals were intraperi-
toneally injected with RA (100 mg/100 g BW) and killed 24 h later.
Total RNA was isolated from lung and heart and IGF-IR mRNA
content determined. Lungmembranes were obtained and IGF-I bind-
ing measured, as indicated in Materials and Methods. Tx, hypothy-
roid. The bars represent SD.
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be down-regulated by GH in cells in culture (31) and in
female rats (32), our results indicate that GH does not me-
diate the effect of T3 on IGF-IR gene expression in lung and
heart, because its administration to hypothyroidN-30 did not
modify IGF-I binding. Anothermediator of T3 effect could be
the IGF-I peptide, because the circulating levels and tissue
concentrations of IGF-I are low in hypothyroid animals (14).
Also, IGF-I has been shown to down-regulate its own re-
ceptors (47). Consequently, the low levels of IGF-I could
cause the increased IGF-I binding and IGF-IR mRNA ob-
served in hypothyroid animals. This possibility, however,
seems unlikely because after hormone administration, the
normalization of the number of receptors and mRNA is very
rapid, especially in the heart. Also, no increase in IGF-I re-
ceptors has been reported in the lung and heart of hypoph-
ysectomized rats in spite of the marked reduction in serum
and tissue levels of IGF-I (48). In other tissues, like spleen,
hypophysectomy has been reported not to alter IGF-IR
mRNA levels (49), and contradictory results have been re-
ported in kidney (50, 51). On the other hand, because thyroid
hormone receptors are present in the heart and lungs of
adults and developing rats (52), an effect of T3 at the cellular
level in these tissues seems to be the most probable
explanation.
RA receptor is a close relative of thyroid hormone receptor,
and both share the regulation of multiple genes (33). We also
have shown in this work that in adult animals, RA increases
IGF-I binding and IGF-IR mRNA, both effects being quan-
titatively larger in the heart compared with the lung. The
effect of RA is not dependent on the thyroidal state of the
animal, because this effect was observed also in control rats,
and it is exerted at a pretranslational level in both tissues
studied. This action of RA has not been shown previously,
although there were some indications that vitamin A and its
derivatives could exert some effects on IGFs and IGFBPs
(53, 54).
In summary, we have showed a tissue-specific increase in
IGF-IR gene expression in the lung and heart in animals
deprived of T3, animals in which the IGFs/IGF-IR system is
profoundly depressed. These results suggest a mechanism
by which the negative consequences of hypothyroidism can
be mitigated in organs as important as the heart and lung.
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